Cambridge Isotope Laboratories, Inc. (CIL) is a global leader in the production and distribution of stable isotopes and stable isotope-labeled compounds. Founded in 1981 by Dr. Joel Bradley, an organic chemist from MIT, CIL has grown to become the largest and most trusted supplier of stable isotopes in the world.
With over 700 employees and laboratories in five countries, CIL specializes in the process of labeling biochemical and organic compounds with highly enriched, stable isotopes of carbon, hydrogen, nitrogen and oxygen. Our innovative technology allows us to substitute a common atom for a rare, highly valued isotopic component, making the final product easily traceable and measurable using mass spectrometry or nuclear magnetic resonance.
CIL's products are utilized in a variety of industries, including medical, government, academic research centers, and healthcare facilities worldwide. Our products have contributed to groundbreaking advancements in cancer research, new drug development, environmental analysis, genomics and proteomics, and medical diagnostics.
At CIL, we are committed to maintaining the highest quality standards in our products and processes. We hold ISO 13485 certification for our quality management systems and have cGMP production capabilities. This dedication to quality has earned us the trust and loyalty of our customers.
The CIL group is comprised of six companies: Cambridge Isotope Laboratories, Inc. (CIL), CIL Isotope Separations (CIS), CIL Canada, Inc. in Montreal, Canada; Euriso-Top in Saclay, France; ABX GmbH in Dresden, Germany; and CIL China. Each of these companies plays a vital role in our global operations, allowing us to provide our customers with the best possible service and products.
At CIL, we are passionate about our mission to advance scientific research and improve human health through our stable isotope products. With our cutting-edge technology, dedicated team, and commitment to quality, we continue to lead the way in the stable isotope industry.